Case reports that linked GLP-1s to suicidality have raised regulatory concerns and left many wondering if these medications are harming the patients they intend to help, Laurent Azoulay, PhD , a professor and William Dawson Scholar at McGill University and a senior investigator at the Jewish General Hospitals Lady Davis Institute in Montreal, Canada, told Healio
Keep away from hands, nose, mouth and exposed wounds
Since GLP-1 drugs mimic a hormone, could the same be true for these medications
two patients had only obesity
PSPeptides offers a structurally different shipping proposition
The results for orforglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, show less dramatic weight loss than injectable medications but are still clinically meaningful, according to the manufacturer Eli Lilly